collaborators

1 paper

stat.AP2023

Integration of Efficacy Biomarkers Together with Toxicity Endpoints in Immune-Oncology Dose Finding Studies

Yiding Zhang, Zhixing Xu, Hui Quan +1

The primary objective of phase I oncology studies is to establish the safety profile of a new treatment and determine the maximum tolerated dose (MTD). This is motivated by the dev…